Screener
Protagonist Therapeutics PTGX Ratios & Valuation
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | 20.7%+9.2pp | -192.4%-205pp | -343.6%-402pp | 9.1%— | 11.5%— | |
| Net margin | 29.4%+4.5pp | -154.9%-182pp | -282.8%-346pp | 21.9%— | 24.9%— | |
| Returns | ||||||
| Return on equity | 11%+2.4pp | -17.1%-26.1pp | -20.2%-74.6pp | 7.8%— | 8.6%— | |
| Return on invested capital | 12.2%+5.6pp | -27.6%-33.2pp | -29.1%-96.4pp | 3.8%— | 6.6%— | |
| Efficiency | ||||||
| Asset turnover | 0.4×0.0× | 0.1×-0.2× | 0.1×-0.7× | 0.3×-0.4× | 0.3×-0.4× | |
| Liquidity | ||||||
| Current ratio | 21.7×+4.7× | 17.8×+0.5× | 12.7×+0.2× | 13×+2.4× | 17×+3.2× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Net debt / EBITDA | -6.9×-0.5× | —— | —— | -5.1×— | -6.3×— | |
| Per Share | ||||||
| Book value per share | $11.85+12.7% | $9.30-15.0% | $9.67-6.8% | $10.12+17.5% | $10.52+19.1% | |
| Valuation | ||||||
| Market capitalization | $8.83B+165% | $6.73B+127% | $5.46B+137% | $4.13B+49.8% | $3.33B+57.8% | |
| Price / earnings | 106.5×+42.4× | —— | —— | 90×— | 63.9×— | |
| Price / sales | 31.3×+15.4× | 90.8×+76.5× | 118.7×+113× | 19.8×+11.2× | 15.9×+9.3× | |
| Price / book | 10.5×+5.5× | 10.3×+6.0× | 8.9×+5.5× | 6.4×+1.2× | 5×+1.1× | |
| EV / EBITDA | 140.6×+12.7× | —— | —— | 201.2×— | 127.5×— |
FAQ
- Where do Protagonist Therapeutics's ratios come from?
- Every ratio is computed from Protagonist Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
